The Molecular Basis of Differential Subcellular Localization of C2 Domains of Protein Kinase C-alpha and Group IVa Cytosolic Phospholipase A2*

Robert V. Stahelin, John D. Rafter, Sudipto Das, and Wonhwa ChoDagger

From the Department of Chemistry, University of Illinois at Chicago, Chicago, Illinois 60607

Received for publication, December 17, 2002, and in revised form, January 15, 2003

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The C2 domain is a Ca2+-dependent membrane-targeting module found in many cellular proteins involved in signal transduction or membrane trafficking. C2 domains are unique among membrane targeting domains in that they show a wide range of lipid selectivity for the major components of cell membranes, including phosphatidylserine and phosphatidylcholine. To understand how C2 domains show diverse lipid selectivity and how this functional diversity affects their subcellular targeting behaviors, we measured the binding of the C2 domains of group IVa cytosolic phospholipase A2 (cPLA2) and protein kinase C-alpha (PKC-alpha ) to vesicles that model cell membranes they are targeted to, and we monitored their subcellular targeting in living cells. The surface plasmon resonance analysis indicates that the PKC-alpha C2 domain strongly prefers the cytoplasmic plasma membrane mimic to the nuclear membrane mimic due to high phosphatidylserine content in the former and that Asn189 plays a key role in this specificity. In contrast, the cPLA2 C2 domain has specificity for the nuclear membrane mimic over the cytoplasmic plasma membrane mimic due to high phosphatidylcholine content in the former and aromatic and hydrophobic residues in the calcium binding loops of the cPLA2 C2 domain are important for its lipid specificity. The subcellular localization of enhanced green fluorescent protein-tagged C2 domains and mutants transfected into HEK293 cells showed that the subcellular localization of the C2 domains is consistent with their lipid specificity and could be tailored by altering their in vitro lipid specificity. The relative cell membrane translocation rate of selected C2 domains was also consistent with their relative affinity for model membranes. Together, these results suggest that biophysical principles that govern the in vitro membrane binding of C2 domains can account for most of their subcellular targeting properties.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The agonist-induced subcellular targeting of protein is an important process in cell signaling and regulation. Recently, the membrane targeting of peripheral proteins (e.g. phospholipases, lipid-dependent protein kinases, lipid kinases, and lipid phosphatases) by Ca2+ and lipid mediators, including phosphoinositides, has received much attention as an important event in cell signaling and membrane trafficking. It has been shown that the subcellular targeting of peripheral proteins is driven by a growing number of membrane targeting domains. These domains include protein kinase C (PKC)1 conserved 1 (C1) domain, PKC conserved 2 (C2) domain, pleckstrin homology (PH) domain, Fab1, YOTB, Vac 1 and EEA1 (FYVE) domain, band four-point-one, ezrin, radixin and moesin (FERM) domain, epsin amino-terminal homology (ENTH) domain, and phox (PX) domains (1-5).

The C2 domain has been identified in many cellular proteins involved in signal transduction or membrane trafficking (5-7). A majority of C2 domains bind the membrane in a Ca2+-dependent manner and thereby play an important role in Ca2+-dependent membrane targeting of peripheral proteins. Structural analyses of Ca2+-dependent membrane binding C2 domains have demonstrated similar tertiary structures in which three Ca2+ binding loops are located at an end of eight-stranded antiparallel beta -sandwich (8-14). Despite similar structural folds, C2 domains exhibit great functional diversities due to local structural variations, particularly in the Ca2+ binding loops. Most Ca2+-dependent membrane binding C2 domains have higher affinity for anionic membranes than for zwitterionic ones. In particular, the C2 domains of PKC-alpha (PKC-alpha -C2) and phospholipase C-delta 1 show selectivity for phosphatidylserine (PS) (15-17). In contrast, the C2 domains of group IVa cytosolic phospholipase A2 (cPLA2) (18) and 5-lipoxygenase (19) strongly favor zwitterionic phosphatidylcholine (PC). Furthermore, C2 domains show distinct subcellular localization patterns. For instance, the C2 domains of PKC-alpha (20) and phospholipase C-delta 1 (17) translocate to the plasma membrane, whereas the C2 domains of cPLA2 (cPLA2-C2) (21, 22) and 5-lipoxygenase (19) translocate to the perinuclear region. Although recent studies indicate that the Ca2+ binding loops are involved in lipid selectivity of C2 domains (17, 19, 23, 24), the mechanisms of differential lipid selectivity and distinct subcellular localization of C2 domains have not been fully elucidated. To understand these mechanisms, we performed biophysical studies using purified recombinant proteins and vesicles whose lipid compositions resemble those of cell membranes and measured the spatiotemporal dynamics of enhanced green fluorescent protein (EGFP)-tagged C2 domains and mutants in live cells. These studies not only identify the residues that are responsible for their distinct lipid selectivity but also demonstrate that in vitro membrane binding properties of C2 domains are quantitatively correlated with their subcellular targeting behaviors.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC),1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoinositol (POPI), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoserine (POPS), and cholesterol were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL) and used without further purification. Phospholipid concentrations were determined by phosphate analysis (25). The Liposofast microextruder and 100-nm polycarbonate filters were from Avestin (Ottawa, Ontario). Fatty acid-free bovine serum albumin was from Bayer Inc. (Kankakee, IL). Triton X-100 was obtained from Pierce Chemical Co. (Rockford, IL). Restriction endonucleases and enzymes for molecular biology were obtained from either Roche Molecular Biochemicals or New England BioLabs (Beverly, MA). CHAPS and octyl glucoside were from Sigma and Fisher Scientific, respectively. Pioneer L1 sensor chip was from Biacore AB (Piscataway, NJ).

Mutagenesis and Protein Expression-- The isolated cPLA2-alpha -C2 and mutants (26) and the isolated PKC-alpha -C2 and mutants (15) were expressed and purified as previously described. Mutants of PKC-alpha -C2 were generated by the overlap extension PCR (27) using pVL1392-PKC-alpha plasmid as a template (28). Briefly, four primers, including two complementary oligonucleotides introducing a desired mutation and two additional oligonucleotides complementary to the 5'-end of the C2 domain (residue 154) and the 3'-end (284) of the PKC-alpha gene, respectively, were used for PCR performed in a DNA thermal cycler (PerkinElmer Life Sciences) using Pfu DNA polymerase (Stratagene). Two DNA fragments overlapping at the mutation site were first generated and purified on an agarose gel. These two fragments were then annealed and extended to generate an entire C2 domain gene containing a desired mutation, which was further amplified by PCR. The product was subsequently purified on an agarose gel, digested with NcoI and XhoI, and subcloned into the pET21d vector digested with the same restriction enzymes. The mutagenesis was verified by DNA sequencing using a T7 Sequenase kit (U.S. Biochemical, Cleveland, OH).

Construction of Gene Constructs of cPLA2 and PKC-alpha Fused with EGFP-- EGFP in pEGFP vector (Clontech) was modified by PCR to remove the first methionine and to add two amino-terminal glycines and an EcoRI site. The modified EGFP gene was inserted into a modified pIND vector (Invitrogen) between the EcoRI and XhoI sites to yield a plasmid, pIND/EGFP. PKC-alpha was cloned by PCR to remove the stop codon and add two carboxyl-terminal glycines and an EcoRI site. The PCR product was digested with NotI and EcoRI and ligated into pIND/EGFP to generate a carboxyl-terminal EGFP fusion PKC-alpha with spacer sequence GGNSGG. PKC-alpha -C2 mutants and cPLA2-C2 constructs were generated by the same method. Two chimera proteins were prepared as follows: The C2 domain of PKC-alpha was cloned out using PCR to introduce a 5' NotI site and a 3' SmaI site. The catalytic domain of cPLA2 was cloned out to have a 5' SmaI site and a 3' BglII site. The catalytic domain of cPLA2 was first digested and ligated into the pUC18 vector. After this sequence was confirmed, the C2 domain of PKC-alpha was digested and ligated into the pUC18 vector between NotI and SmaI sites. After confirming this sequence, it was cloned using PCR to contain a 5' NotI site and a 3' BglII site and subsequently ligated into the modified pIND/EGFP vector to possess the EGFP at the N terminus. The catalytic domain of PKC-alpha was cloned using PCR to contain a 5' PstI site and a 3' EcoRI site and to remove the stop codon. The C2 domain of cPLA2 was then cloned to possess a 5' SmaI site and a 3' PstI site while the regulatory domain preceding the C2 domain of PKC-alpha was cloned to have a 5' NotI site and a 3' SmaI site. All were digested with restriction enzymes for their respective recognition end sequences and then ligated stepwise into the pUC18 vector cut with the same restriction enzymes. Each fragment was verified for correct positioning within the vector before the next fragment was ligated in (i.e. the catalytic domain was checked for its correctness before the C2 domain was ligated into this vector). After sequence confirmation, this chimera was cloned using PCR to have a 5' NotI site and a 3' EcoRI site and ligated into modified pIND/EGFP vector to possess a carboxyl-terminal EFGP.

SPR Measurements-- The preparation of vesicle-coated Pioneer L1 sensor chip (Biacore) was described in detail elsewhere (29, 30). In control experiments, the sensor chip was coated with vesicles (e.g. POPC/POPS (7:3)) incorporating 10 mM 5-carboxyfluorescein (Molecular Probes), and the fluorescence intensity of the flow buffer was monitored to confirm that the vesicles remained intact on the chip. All experiments for cPLA2-C2 were performed with a control cell in which a second sensor surface was coated with bovine serum albumin. For all PKC experiments, the control sensor surface was coated with 100% POPC for which PKC-alpha -C2 has extremely low affinity. The drift in signal for both sample and control flow cells was allowed to stabilize below 0.3 resonance unit/min before any kinetic experiments were performed. All kinetic experiments were performed at 24 °C and a flow rate of 60 µl/min. A high flow rate was used to circumvent mass transport effects. The association was monitored for 90 s and dissociation for 4 min.

The immobilized vesicle surface was then regenerated for subsequent measurements using 10 µl of 50 mM NaOH. The regeneration solution was passed over the immobilized vesicle surface until the SPR signal reached the initial background value before next protein injection. For data acquisition, five or more different concentrations (typically within a 10-fold range above or below the Kd) of each protein were used. After each set of measurements, the entire immobilized vesicles were removed by injection of 25 µl of 40 mM CHAPS, followed by 25 µl of octyl glucoside at 5 µl/min, and the sensor chip was re-coated with a fresh vesicle solution for the next set of measurements.

All data were evaluated using BIAevaluation 3.0 software (Biacore). After sensorgrams were corrected for refractive index changes, the association and dissociation phases of all sensorgrams were globally fit to a 1:1 Langmuir binding model: protein + (protein binding site on the vesicle) left-right-arrow (complex) using BIAevaluation 3.0 software (Biacore). The association phase was analyzed using an equation, R = [kaC/(kaC + kd)]Rmax(1 - e-(kaC + kd)(t - t0)) + RI, where RI is the refractive index change, Rmax is the theoretical binding capacity, C is the protein concentration, ka is the association rate constant, and t0 is the initial time. The dissociation phase was analyzed using an equation, R = R0e-kd(t - t0), where kd is the dissociation rate constant and R0 is the initial response. The dissociation constant (Kd) was then calculated from the equation, Kd = kd/ka. It should be noted that in our SPR analysis Kd is defined in terms not of the molarity of phospholipids but of the molarity of protein binding sites on the vesicle. Thus, if each protein binding site on the vesicle is composed of n lipids, nKd is the dissociation constant in terms of molarity of lipid monomer (31). Due to difficulty involved in accurate determination of the concentration of lipids coated on the sensor chip, only Kd was determined in our SPR analysis, and the relative affinity was calculated as a ratio of Kd values assuming that n values are essentially the same for wild type and mutants. Mass transport (32, 33) was not a limiting factor in our experiments, as change in flow rate did not affect kinetics of association and dissociation.

Cell Culture-- A stable HEK293 cell line expressing the ecdysone receptor (Invitrogen) was used for all experiments. Briefly, cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37 °C in 5% CO2 and 98% humidity until 90% confluent. Cells were passaged into eight wells of a Lab-TechTM chambered cover glass for later transfection and visualization. Only cells between the 5th and 20th passages were used.

Transfection and Protein Production-- 80-90% confluent cells in Lab-TechTM chambered cover glass wells were exposed to 150 µl of unsupplemented DMEM containing 0.5 µg of endotoxin-free DNA and 1 µl of LipofectAMINETM reagent (Invitrogen) for 7-8 h at 37 °C. After exposure, the transfection medium was removed, and the cells were washed once with FBS-supplemented DMEM then overlaid with FBS-supplemented DMEM containing ZeocinTM (Invitrogen) and 5 µg/ml ponasterone A (Invitrogen) to induce protein production.

Confocal Microscopy-- Images were obtained using a four-channel Zeiss LSM 510 laser scanning confocal microscope. All experiments were carried out at the same laser power, which was found to induce minimal photobleaching over 30 scans, and at the same gain and offset settings on the photomultiplier tube. Also, a 63×, 1.2 numerical aperture water immersion objective was used for all experiments. EGFP was excited using the 488-nm line of an argon/krypton laser and a line pass 505-nm filter was used to monitor EGFP emission on channel 1. We used mag-indo-1 for real-time monitoring of changes in intracellular calcium concentration ([Ca2+]i) in the micromolar range. For simultaneous monitoring of EGFP and [Ca2+]i, mag-indo-1 was excited using the 340-nm line of a UV laser, and the emitted light was collected using band pass filters (395-425 and 450-490 nm) on a second channel. The LSM 510 imaging software was used to control the time intervals for imaging. Ca2+-dependent translocation of C2 domains was monitored as follows: Thirty minutes before imaging, cells were treated with 2 µl of mag-indo-1 (10 µM final concentration) (Molecular Probes). Immediately before imaging, the induction media was removed and the cells were washed with 150 µl of 2 mM EGTA and then overlaid with 150 µl of HEK buffer (1 mM HEPES, pH 7.4, containing 2.5 mM MgCl2, 1 mM NaCl, 0.6 mM KCl, 0.67 mM D-glucose, 6.4 mM sucrose). After initially imaging cells, 150 µl of HEK buffer containing 10 µM ionomycin and 1 mM CaCl2 was added to the cells. Protein translocation was monitored by time scanning at 4-s intervals for PKC-alpha -C2 and at 15-s intervals for cPLA2-C2. [Ca2+]i in the cytoplasm was determined at 4- to 15-s intervals using the equation, [Ca2+]i = Kca × Q × (R - Rmin)/(Rmax - R) (34), where R represents the fluorescence intensity ratio F410/F470 that was determined from the average background-corrected pixel values of mag-indo-1 fluorescence from the cytoplasmic area of individual cells at 410 and 470 nm, respectively; Rmin and Rmax correspond to minimum and maximum fluorescence intensity ratios at no Ca2+ and saturating calcium levels (i.e. 1 mM free Ca2+), respectively. Q is the ratio of the minimum fluorescence intensity at zero free calcium (Fmin) to the maximum fluorescence intensity at 1 mM saturating calcium (Fmax) at 470 nm, and Kca is the calcium dissociation constant for mag-indo-1. Rmin, Rmax, Q, and Kca values were determined by in vitro calcium calibration using 1 µM mag-indo-1 and a set of standard calcium buffers (Molecular Probes) containing 0-1 mM free Ca2+. The calculated Kca (34 ± 1 µM) was the same as the reported value of 35 µM (35).

Cell Imaging Data Analysis-- Images were analyzed using the analysis tools provided in the Zeiss biophysical software package. Using these tools, regions of interest in the cytosol were defined, and the average intensity in a square (1 µM × 1 µM) was obtained with time. Membrane intensities were determined for each frame in individual cells by extending a line from the cytosol to the outside of the cell and recording the intensity with distance along the line. By cross-checking markers on the diagram with a table of intensity data, four intensity values corresponding to the place on the line indicating the edge of the cell were averaged. Lines were drawn in at least three places in each cell, and membrane intensity values were determined and averaged. Intensity values outside the photomultiplier tube's linear range were discarded. The resultant intensity values were converted to a ratio of intensity at membrane to the sum of intensities at membrane and at cytosol for each time frame. Membrane translocation rates of individual C2 domains were then calculated from the slopes of these plots by linear regression. Each experiment was repeated at least twice on a given day, and was repeated on at least two different days with different transfected cells. Cellular distribution of EGFP intensity throughout the cell was obtained using the profile function on the software package. A line was drawn through the cell from an arbitrary point, and the EFGP intensity from each point along the line was plotted versus arbitrary distance to correlate the difference in EGFP intensities at different subcellular locations.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

PS Selectivity of PKC-alpha -C2-- The C2 domain of PKC-alpha has been shown to have PS selectivity with extremely low affinity for zwitterionic phospholipids (i.e. PS > PG PC) (15). Our structure-function analysis of PKC-alpha (15) and its isolated C2 domain (36) and the crystal structure of PKC-alpha -C2 (12) suggested that the PS selectivity derive from the specific recognition of PS by a C2 domain-bound calcium ion and several residues located in the calcium binding loops (Fig. 1). In particular, a recent mutation study on PKC-alpha showed that Asn189, Arg216, Arg249, and Thr251 in the calcium binding loops are involved in PS binding (24). However, it is still unclear whether these residues are involved in specific headgroup recognition or in binding to other parts of phospholipid molecule. We therefore measured the effect of the mutations of these residues on the lipid headgroup selectivity. We also mutated another cationic residue (Arg252) that has been implicated in membrane binding (28). PS selectivity of wild type and mutants was determined by comparing their binding affinity for immobilized POPC/POPS (7:3) and POPC/POPG (7:3) vesicles by SPR analysis. PKC-alpha -C2 shows extremely low affinity for POPC vesicles. This allowed the use of the physiologically more relevant mixed vesicles in lieu of 100% POPS or POPG vesicles for identifying the residues directly involved in specific lipid headgroup recognition (i.e. serine versus glycerol headgroup).


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 1.   Structures of calcium binding loops of PKC-alpha -C2 and cPLA2-C2. PKC-alpha -C2 (aqua) and cPLA2-C2 (orange) are shown in ribbon diagrams with two Ca2+ ions (magenta) bound to the domains. Side chains of mutated residues are shown and labeled. The coordinates for PKC-alpha -C2 and cPLA2-C2 were taken from the crystal structures solved by Verdaguer et al. (12) and by Perisic et al. (13), respectively. PKC-alpha -C2 achieves its PS selectivity by specific headgroup recognition by Asn189 and other interactions involving a Ca2+ ion, Arg216, and Thr251. For cPLA2-C2, Phe35, Leu39, Tyr96, and Val97 are all involved in PC selectivity.

We have shown that the SPR analysis allows direct determination of membrane association (ka) and dissociation (kd) rate constants for peripheral proteins (29, 31). As summarized in Table I, PKC-alpha -C2 has higher affinity (in terms of Kd) for POPC/POPS (7:3) than for POPC/POPG (7:3), and the PS selectivity of PKC-alpha -C2 expressed in term of the ratio of 1/Kd for POPC/POPS (7:3) to 1/Kd for POPC/POPG (7:3) is about 11. Interestingly, the higher affinity for PS is almost entirely ascribed to the lower kd value. Our previous study indicated that nonspecific electrostatic interactions primarily accelerate the association of protein to anionic membrane surfaces, whereas hydrophobic interactions and short-range specific interactions (electrostatic or hydrogen bonds) mainly slow the membrane dissociation (29). Thus, the present data support the notion that PS forms specific interactions with the PKC-alpha -C2.


                              
View this table:
[in this window]
[in a new window]
 
Table I
Binding parameters for PKC-alpha -C2 and mutants determined from SPR analysis
Values represent the mean ± S.D. from five determinations. All measurements were performed in 10 mM HEPES, pH 7.4, containing 0.1 M NaCl and 0.1 mM Ca2+.

The previous study showed that the T251A mutation had the most detrimental effect on binding affinity for PS-containing vesicles and micelles, whereas N189A, R216A, and R249A exhibited lesser effects (24). Our SPR data also showed that T251A reduced the affinity for POPC/POPS (7:3) vesicles more significantly than N189A, R216A, and R249A/R252A. T251A has 18-fold lower affinity than wild type, whereas N189A, R216A, and R249A/R252A have 5- to 6-fold lower affinity. Most important, T251A, R216A, and R249A/R252A have essentially the same PS selectivity as the wild type, because the mutations reduced the affinity of PKC-alpha -C2 for POPC/POPS (7:3) and POPC/POPG (7:3) vesicles to comparable degrees. In contrast, the N189A mutation reduced the PS affinity of PKC-alpha -C2 5-fold without affecting its PG affinity. As a result, N189A exhibited much reduced 2-fold PS selectivity. Together, these data indicated that Asn189 is involved in specific PS headgroup binding, whereas other mutated residues are involved in either binding to a non-headgroup part of an anionic phospholipid, such as sn-1 or -2 acyl group, or nonspecific binding to the anionic membrane surface.

Examination of effects of mutations on ka and kd provided a further insight into their roles. For binding to POPC/POPS (7:3) vesicles, the N189A, R216A, and T251A mutations changed kd more than ka, whereas the R249A/R252A mutation primarily reduced the ka value (see Table I). This indicates that Arg216 and Thr251 are involved in specific short-range interactions with a non-headgroup part of PS molecule and that Arg249 and Arg252 participate in nonspecific electrostatic interactions with the anionic membrane surface.

PC Selectivity of cPLA2-C2-- The C2 domain of cPLA2 contains multiple aliphatic and aromatic residues, including Phe35, Leu39, Tyr96, and Val97, in its calcium binding loops (see Fig. 1) that have been shown to partially penetrate the membrane during the membrane binding of cPLA2-C2 (26). It has been also known that cPLA2-C2 has PC selectivity (18). However, the origin of this selectivity has yet to be elucidated. To identify the residues in the cPLA2-C2 that are responsible for its PC selectivity, we mutated aromatic and aliphatic residues in the Ca2+ binding loops and measured their membrane binding by SPR analysis. In this case, we measured the affinities of wild type and mutants for 100% POPC and POPS vesicles. As listed in Table II, cPLA2-C2 prefers POPC to POPS by a factor of 11 in terms of Kd, confirming PC selectivity of cPLA2-C2. The mutations of all four hydrophobic residues reduced the affinity of cPLA2-C2 for PC membrane by more than two orders of magnitude. Furthermore, the mutations of two aromatic residues (Phe35 and Tyr96) affected ka and kd to comparable degree, whereas those of two aliphatic residues (Leu39 and Val97) primarily increased kd. This again underscores the difference between aliphatic and aromatic residues in their interfacial interactions. Most importantly, all mutants showed dramatically reduced PC selectivity: their PC selectivity expressed in terms of the ratio of (1/Kd) for POPC to (1/Kd) for POPS ranges from 0.6 to 1.1, indicating that all four residues in the calcium binding loops are involved in PC selectivity.


                              
View this table:
[in this window]
[in a new window]
 
Table II
Binding parameters for cPLA2-C2 and mutants determined from SPR analysis
Values represent the mean ± S.D. deviation from five determinations. All measurements were performed in 10 mM HEPES, pH 7.4, containing 0.1 M NaCl and 0.1 mM Ca2+.

Binding of cPLA2-C2 and PKC-alpha -C2 to Cell Membrane Mimic Vesicles-- It has been shown that the C2 domains of conventional PKCs (alpha , beta I, beta II, and gamma ) translocate to the plasma membrane (20, 37) and cPLA2-C2 to the perinuclear region in response to Ca2+ import (21, 22). Also, this subcellular localization pattern of isolated C2 domains correlates with that of peripheral proteins harboring the C2 domains; i.e. conventional PKCs translocate to plasma membrane (38-41) while cPLA2 moves to perinuclear region (42, 43). Although vesicles used in the preceding measurements serve well for determining the lipid selectivity of the C2 domains and mutants, they do not fully represent the cytoplasmic plasma membrane and the cytoplasmic nuclear envelope that PKC-alpha -C2 and for cPLA2-C2, respectively, are targeted to. To better understand the subcellular targeting behaviors of the C2 domains, we measured their binding to immobilized vesicles whose lipid compositions recapitulate those of cellular membranes.

The lipid compositions of the cytoplasmic plasma membrane and the cytoplasmic nuclear envelope were predicted from the reported lipid compositions of rat liver cell membranes (44) and by making a few experimentally supported but simplifying assumptions. The assumptions were: (i) that half of the lipid molecules are present in each leaflet; (ii) that a large majority of phosphatidylethanolamine (80%), phosphatidylinositol (80%), and PS (95%) are present in the cytoplasmic leaflet of the plasma membrane, whereas a majority of PC (70%) and sphingomyelin (>90%) are in the outer leaflet (45); and (iii) that all phospholipids are equally distributed between the cytoplasmic and the nucleoplasmic leaflets of nuclear membranes. This simple approximation yielded POPC/POPE/POPS/POPI/cholesterol (12:35:22:9:12, molar ratio) as a cytoplasmic plasma membrane mimic and POPC/POPE/POPS/POPI/cholesterol (61:21:4:7:7, molar ratio) as a cytoplasmic nuclear membrane mimic, respectively. Table III summarizes the parameters for binding of the C2 domains and their respective mutants to these vesicles determined from SPR analysis.


                              
View this table:
[in this window]
[in a new window]
 
Table III
Cell membrane mimic binding parameters for C2 domains and mutants determined from SPR analysis
Values represent the mean ± S.D. from three determinations. All measurements were performed in 10 mM HEPES, pH 7.4, containing 0.1 M KCl and 0.1 mM Ca2+.

PKC-alpha -C2 showed about 30-fold higher affinity for the plasma membrane mimic than for POPC/POPS (7:3) vesicles, despite lower PS content in the former. This suggests that the presence of PE and/or cholesterol enhances the membrane affinity of PKC-alpha -C2. Intriguingly, the mutation of Asn189 that is directly involved in PS headgroup interaction resulted in a large 34-fold drop in affinity, whereas the double mutation of Arg249 and Arg249 led to 5-fold decrease in affinity, which is comparable to the data obtained with POPC/POPS (7:3) vesicles. Thus, it would seem that specific PS coordination is critical for interaction of PKC-alpha -C2 to the plasma membrane, which was not fully expressed when binding assay was performed with POPC/POPS (7:3) vesicles. Most importantly, PKC-alpha -C2 and R249A/R252A greatly (i.e. 121-fold and 114-fold, see Table III) preferred the plasma membrane mimic to the nuclear envelope mimic, whereas N189A showed dramatically reduced 10-fold selectivity for the plasma membrane mimic. This suggests that N189A might be targeted to the nuclear envelope in addition to the plasma membrane under certain physiological conditions.

cPLA2-C2 also showed higher (i.e. 5-fold) affinity for the nuclear envelope mimic than for POPC vesicles. For the nuclear envelope mimic, L39A, Y96A, and V97A had 100-fold, 310-fold, and 43-fold lower affinity, respectively, than wild type. Importantly, cPLA2-C2 exhibited 33-fold selectivity for the nuclear envelope mimic, whereas all mutants of cPLA2-C2, including L39A, Y96A, and V97A, had much reduced 3- to 5-fold selectivity. This again suggests that these mutants might be targeted to both nuclear envelope and plasma membrane in the cell. Lastly, affinity of PKC-alpha -C2 for the plasma membrane mimic is 4.5-fold higher than that of cPLA2-C2 for the nuclear envelope mimic due in large part to larger ka for PKC-alpha -C2. This suggests that PKC-alpha -C2 might respond faster than cPLA2-C2 in response to a rise in [Ca2+]i under the same conditions.

Subcellular Translocation of cPLA2-C2 and PKC-alpha -C2-- It remains unknown whether specific subcellular localization of C2 domains are due to their different lipid specificities or the presence of specific adapter proteins for individual proteins. To address this question, we transiently transfected HEK293 cells with isolated C2 domains, mutants, full-length cPLA2, and full-length PKC-alpha , all tagged with EGFP at their carboxyl termini, and determined their spatiotemporal dynamics by time-lapse confocal microscopy. In control experiments, all EGFP-tagged proteins showed the membrane binding affinities comparable to those of their non-tagged counterparts when assayed by SPR analysis under the same conditions (data not shown). Also, transfected cells expressed the corresponding proteins when tested by Western blotting analysis of lysed cells (data not shown). As shown in Fig. 2, both cPLA2-C2-EGFP and PKC-alpha -C2-EGFP are evenly dispersed in the cytoplasm when cells were incubated in a Ca2+-depleted medium. When cells were activated with 2 µM ionomycin that gave rise to ~0.5 µM [Ca2+]i, wild type C2 domains, PKC-alpha -C2 in particular, showed rapid membrane translocation, but most of the mutants with reduced membrane affinity did not migrate even after 30 min (data not shown). We therefore activated the cells with 10 µM ionomycin and 1 mM CaCl2, which resulted in sustained [Ca2+]i level at ~70 µM (Fig. 3). It should be noted that, although this does not reflect a physiological condition, it allowed quantitative determination of translocation rates of wild type and mutant proteins under the same experimental conditions. Upon calcium activation, PKC-alpha -C2-EGFP rapidly moved to the plasma membrane, which was synchronized with the [Ca2+]i change as observed by mag-indo 1 imaging (Fig. 3). In contrast, cPLA2-C2 moved more slowly to the perinuclear region that includes the nuclear envelope and the endoplasmic reticulum, which is consistent with its lower affinity and smaller ka than PKC-alpha -C2.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 2.   Subcellular translocation of PKC-alpha -C2 and cPLA2- C2 upon calcium activation. HEK293 cells treated with Mag-indo-1 were washed with 2 mM EGTA and then overlaid with HEK buffer for PKC-alpha -C2 (A) or cPLA2-C2 (B). Cells were then activated by adding 10 µM ionomycin and 1 mM calcium. Cell images were taken every 4 s for PKC-alpha -C2 and every 15 s for cPLA2-C2, respectively.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 3.   Change in [Ca2+]i and subcellular translocation of PKC-alpha -C2 and cPLA2-C2 upon calcium activation. Experimental conditions are the same as described for Fig. 2. A, the time-lapse changes in EGFP intensity ratio at the plasma membrane (= plasma membrane/[plasma membrane + cytoplasm]) for PKC-alpha -C2 (open circle ) and R249A/R252A (triangle ) and the change in [Ca2+]i in the cytoplasm (). B, the time-lapse changes in EGFP intensity ratio at the perinuclear region (= nuclear membrane/[nuclear membrane + cytoplasm]) for cPLA2-C2 (open circle  and the change in [Ca2+]i in the cytoplasm ().

Also, full-length PKC-alpha and cPLA2 showed the same subcellular targeting patterns as their respective C2 domains (Fig. 4). Furthermore, the time dependences of their subcellular localization (data not shown) were reminiscent of those of respective isolated C2 domains shown in Fig. 2. This suggests that subcellular targeting of these proteins is driven by their C2 domains under the given conditions. To further verify this notion we measured the subcellular targeting behaviors of chimera proteins. As shown in Fig. 4, a chimera of PKC-alpha containing the C2 domain of cPLA2 migrated to the perinuclear region, whereas a chimera of cPLA2 containing the C2 domain of PKC-alpha translocated to the plasma membrane in response to calcium influx. As was the case with wild type PKC-alpha and cPLA2, the time dependences of their subcellular localization (data not shown) were similar to those of respective isolated C2 domains (Fig. 2).


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 4.   Subcellular translocation of PKC-alpha , cPLA2, and chimera proteins. Experimental conditions are the same as described for Fig. 2. Images represent cells expressing PKC-alpha (A), cPLA2 (B), a cPLA2 chimera harboring the PKC-alpha -C2 (C), and a PKC-alpha chimera containing the cPLA2-C2 (D) before (first column) and 10 min after (second column) the addition of 10 µM ionomycin and 1 mM calcium. Membrane translocation kinetic patterns of full-length proteins were similar to those of the respective isolated C2 domains shown in Fig. 2.

We then measured the subcellular localization of C2 domain mutants. For PKC-alpha -C2, the R249A/R252A mutant translocated to the plasma membrane, whereas N189A with much reduced PS selectivity translocated to both plasma membrane and perinuclear region (Fig. 5). To demonstrate the dual targeting of N189A, we quantitatively determined the cellular distribution of EGFP intensity after Ca2+ stimulation (Fig. 6). Clearly, PKC-alpha -C2 is primarily localized to the plasma membrane, while N189A is localized both at the plasma membrane and at the perinuclear region, albeit more abundantly at the plasma membrane. This supports the notion that specific PS coordination by Asn189 plays a key role in the targeting of PKC-alpha -C2 to the plasma membrane. As was the case with PKC-alpha -C2, the cPLA2-C2 mutants showed expected cellular behaviors. In this case, all mutants showed dual targeting to the plasma membrane and the perinuclear region (see Fig. 5). Fig. 6 demonstrates the difference in cellular EGFP intensity distribution of cPLA2-C2 and Y96A upon Ca2+ stimulation.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 5.   Subcellular localization of PKC-alpha -C2, cPLA2-C2, and respective mutants upon calcium activation. A, PKC-alpha -C2; B, PKC-alpha -C2 N189A; C, cPLA2-C2; D, cPLA2-C2 Y96A; and E, cPLA2-C2 V97A. Experimental conditions are the same as described for Fig. 2. Images represent the subcellular localization patterns of indicated C2 domains before (first column) and 10 min after (second column) the addition of 10 µM ionomycin and 1 mM calcium. An arbitrary line was drawn through each cell to determine the EGFP intensity in each part of the cell. See Fig. 6 for EGFP intensity quantified in each cell.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 6.   Subcellular distribution of EGFP intensity after calcium activation of PKC-alpha -C2, cPLA2-C2, and respective mutants. An EGFP intensity profile was obtained for each cell as described under "Experimental Procedures" (see also Fig. 5). The differential subcellular localization is shown for PKC-alpha -C2 (A), PKC-alpha -C2/N189A (B), cPLA2-C2 (C), and cPLA2-C2/Y96A (D). PM and NE indicate plasma membrane and nuclear envelope, respectively.

Lastly, we determined the membrane translocation rates for the proteins. Those mutants showing dual membrane targeting were excluded in this analysis because of ambiguity involved in determining their membrane targeting rates. As shown in Fig. 7, the R249A/R252A mutant of PKC-alpha -C2 translocated to the plasma membrane 4.4-fold slower than the wild type, which is consistent with its 5-fold lower affinity (and 6-fold smaller ka) for the plasma membrane mimic than the wild type. Furthermore, cPLA2-C2 migrated to the perinuclear region about 7 times slower than PKC-alpha -C2 translocated to the plasma membrane, which is in reasonable agreement with the finding that the former has 4.5-fold lower affinity (and 3.7-fold smaller ka) for the nuclear envelope mimic than the latter has for the plasma membrane mimic. In conjunction with the altered in vitro lipid selectivity of cPLA2-C2 and PKC-alpha -C2 mutants described above, these results support the notion that subcellular targeting by C2 domains is driven by the forces that govern their in vitro membrane binding.


View larger version (54K):
[in this window]
[in a new window]
 
Fig. 7.   Membrane translocation rates for C2 domains and respective mutants. Relative translocation rates calculated from the slopes of the EGFP intensity ratio (membrane/[membrane + cytosol]) versus time plots. Rate values indicate means and standard deviations from a minimum of quadruple determinations.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The membrane binding of proteins involves different types of interactions that depend upon the physicochemical properties of both membrane and protein. Extensive structural and mutational studies of membrane binding proteins have shown that their membrane binding surfaces are composed of cationic, aliphatic, and aromatic residues that drive the membrane binding by electrostatic and non-electrostatic forces (46). Our recent study by surface plasmon resonance analysis indicated that cationic residues primarily accelerate the association of protein to anionic membrane surfaces, whereas aliphatic residues mainly slow the membrane dissociation by penetrating into the hydrophobic core of the membrane (29). Aromatic residues, particularly Trp, play a pivotal role in binding to zwitterionic PC membranes (46, 47) by affecting both membrane association and dissociation steps (29). The present study systematically and quantitatively addresses the question as to whether or not these physicochemical principles governing the in vitro membrane binding of membrane targeting domains also determine their subcellular targeting behaviors, using two C2 domains as a model.

Lipid Selectivity of cPLA2-C2 and PKC-alpha -C2-- A large degree of structural variations have been found in the Ca2+ binding loops of C2 domains in terms of both primary and tertiary structures (8-14,48). Mutational (17, 19, 23, 24, 26, 28), labeling (49, 50), and structural (12-14) studies of C2 domains have identified the residues in the Ca2+ binding loops that play a key role in membrane binding. The present study shows that cationic residues, Arg249 and Arg252, in Ca2+ binding loops of PKC-alpha -C2 are involved in its binding to the anionic membrane surface, whereas Asn189 plays a critical role in PS selectivity. Arg216 and Thr251 are also involved in PS binding but not specifically to the lipid headgroup. These results appear to be at odds with the report by Conesa-Zamora et al. (24) in which Thr251 was shown to play a much more important role than Asn189 in binding to PS-containing membranes as well as in PS-dependent PKC activity. It should be noted, however, that the study by Conesa-Zamora et al. (24) was performed only in the presence of PS-containing membranes: no comparison was made between PS and non-PS membranes. As shown in Table I, we also observed that T251A had the largest impact on the affinity for POPC/POPS (7:3) vesicles. Importantly, however, both T251A and R216A mutations reduced the affinity for POPC/POPS (7:3) and POPC/POPG (7:3) vesicles to comparable degrees. Only the N189A mutation selectively reduced the affinity for PS. This is consistent with the structure of a PKC-alpha -C2·PS complex, which shows that Arg216 and Thr251 primarily interact with sn-1 and sn-2 ester carbonyl moieties, respectively, whereas Asn189 interacts directly with the serine headgroup (12). Also, a smaller effect of the N189A mutation on PS membrane affinity in the study by Conesa-Zamora et al. (24) might be due in part to the fact that not isolated C2 domains but full-length PKC-alpha proteins were used. Presumably, the rest of the PKC-alpha molecule, including the C1 domains, can compensate for the reduced PS affinity caused by the N189A mutation. In the case of cPLA2-C2, both aliphatic and aromatic residues in Ca2+ binding loops are essential for its membrane binding and PC selectivity. Aromatic side chains have been shown to be involved in PC interactions (46, 47); however, the involvement of aliphatic side chains in PC selectivity has not been reported. Further studies are required to understand the origin of this effect.

Subcellular Targeting of cPLA2-C2 and PKC-alpha -C2-- It has been known that conventional PKCs and their C2 domains, including PKC-gamma and its C2 domain (37), PKC-alpha (41), and PKC-alpha -C2 (20), translocate to plasma membrane in response to [Ca2+]i spikes, whereas cPLA2-C2 and cPLA2 are targeted to the perinuclear region upon Ca2+ import (21, 22, 43). However, the origin of these differential subcellular targeting behaviors of PKC C2 domains, cPLA2-C2, and their host proteins is relatively poorly understood. Intuitively, one can assume the presence of site-specific adaptor proteins for these proteins (51, 52). The present study provides quantitative and structural evidence for an alternative view that holds that differential subcellular targeting behaviors of the C2 domains derive mainly from their different lipid selectivity.

It has been reported that mammalian cell membranes have different lipid compositions (44). In particular, the cytoplasmic plasma membrane contains a high PS content (44, 45, 53, 54), whereas the nuclear membrane is relatively rich in PC (44, 55). In this study, the cytoplasmic leaflets of plasma membrane and nuclear envelope were modeled based on the reported lipid compositions of rat liver cell membranes (44). Although the lipid compositions of these vesicles might not reflect the true lipid compositions of cytoplasmic plasma membrane and nuclear envelope of HEK293 cells, they should serve as good models, because kidney and liver cell membranes have similar lipid compositions (44). Consistent with their distinct lipid selectivity, PKC-alpha -C2 and cPLA2-C2 demonstrate pronounced specificity for the plasma membrane and nuclear envelope mimics, respectively (121-fold and 33-fold preference, respectively, for their favorite membranes). Agreement between this strict in vitro specificity and highly specific subcellular localization of the C2 domains suggests that their subcellular targeting is driven primarily by membrane-protein interactions. This notion is further supported by the good correlation between altered lipid specificities of PKC-alpha -C2 and cPLA2-C2 mutants and their subcellular localization. N189A of PKC-alpha -C2 with markedly reduced selectivity for the plasma membrane mimic showed dual targeting to the plasma membrane and the perinuclear region. Likewise, cPLA2-C2 mutants with lower selectivity for the nuclear envelope mimic exhibited the dual targeting behaviors. Similarly, it was shown that the subcellular targeting patterns of the C2 domains of phospholipase C-delta (17) and 5-lipoxygenase (19) can be altered by changing their in vitro lipid selectivity. Lastly, for PKC-alpha -C2, its R249A/R252A mutant, and cPLA2-C2 that translocate to a single cellular destination, the relative affinity (100:20:22, see Table III) for their favorite membrane mimics agrees reasonably well with their relative membrane translocation rate (100:25:15, see Fig. 7).

In sum, these studies indicate that the specific subcellular targeting of PKC-alpha -C2 and cPLA2-C2 derives from their phospholipid headgroup specificities and that one can control the subcellular localization of a C2 domain by altering its lipid selectivity. The studies also demonstrate the semi-quantitative correlation between the in vitro membrane binding of C2 domains and their cellular membrane targeting. A more detailed study is underway to delineate the quantitative correlation between in vitro membrane binding parameters of C2 domains and their cellular responses. Further studies on other membrane targeting domains will answer the question as to whether or not their subcellular targeting could be also explained by biophysical principles that govern their membrane binding.

    ACKNOWLEDGEMENT

We thank Bharath Ananthanarayanan for preparing the PKC-alpha chimera harboring the cPLA2-C2 as well as characterizing its in vitro membrane binding and activation properties.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grants GM52598 and GM53987.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Established Investigator of American Heart Association. To whom correspondence should be addressed: Dept. of Chemistry (M/C 111), University of Illinois at Chicago, 845 W. Taylor St., Chicago, IL 60607-7061. Tel.: 312-996-4883; Fax: 312-996-2183; E-mail: wcho@uic.edu.

Published, JBC Papers in Press, January 16, 2003, DOI 10.1074/jbc.M212864200

    ABBREVIATIONS

The abbreviations used are: PKC-alpha , protein kinase C-alpha ; BSA, bovine serum albumin; cPLA2, cytosolic phospholipase A2; DMEM, Dulbecco's modified Eagle's medium; EGFP, enhanced green fluorescence protein; FBS, fetal bovine serum; PC, phosphatidylcholine; PG, phosphatidylglycerol; POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; POPE, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine; POPG, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol; POPI, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoinositol; POPS, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoserine; PS, phosphatidylserine; RU, resonance unit(s); SPR, surface plasmon resonance; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Hurley, J. H., and Misra, S. (2000) Annu. Rev. Biophys. Biomol. Struct. 29, 49-79[CrossRef][Medline] [Order article via Infotrieve]
2. Hurley, J. H., Tsujishita, Y., and Pearson, M. A. (2000) Curr. Opin. Struct. Biol. 10, 737-743[CrossRef][Medline] [Order article via Infotrieve]
3. Hurley, J. H., and Meyer, T. (2001) Curr. Opin. Cell Biol. 13, 146-152[CrossRef][Medline] [Order article via Infotrieve]
4. Wishart, M. J., Taylor, G. S., and Dixon, J. E. (2001) Cell 105, 817-820[CrossRef][Medline] [Order article via Infotrieve]
5. Cho, W. (2001) J. Biol. Chem. 276, 32407-32410[Free Full Text]
6. Nalefski, E. A., and Falke, J. J. (1996) Protein Sci. 5, 2375-2390[Abstract/Free Full Text]
7. Rizo, J., and Sudhof, T. C. (1998) J. Biol. Chem. 273, 15879-15882[Free Full Text]
8. Shao, X., Davletov, B. A., Sutton, R. B., Sudhof, T. C., and Rizo, J. (1996) Science 273, 248-251[Abstract]
9. Sutton, R. B., Davletov, B. A., Berghuis, A. M., Sudhof, T. C., and Sprang, S. R. (1995) Cell 80, 929-938[Medline] [Order article via Infotrieve]
10. Essen, L. O., Perisic, O., Cheung, R., Katan, M., and Williams, R. L. (1996) Nature 380, 595-602[CrossRef][Medline] [Order article via Infotrieve]
11. Shao, X., Fernandez, I., Sudhof, T. C., and Rizo, J. (1998) Biochemistry 37, 16106-16115[CrossRef][Medline] [Order article via Infotrieve]
12. Verdaguer, N., Corbalan-Garcia, S., Ochoa, W. F., Fita, I., and Gomez- Fernandez, J. C. (1999) EMBO J. 18, 6329-6338[Abstract/Free Full Text]
13. Perisic, O., Fong, S., Lynch, D. E., Bycroft, M., and Williams, R. L. (1998) J. Biol. Chem. 273, 1596-1604[Abstract/Free Full Text]
14. Xu, G. Y., McDonagh, T., Yu, H. A., Nalefski, E. A., Clark, J. D., and Cumming, D. A. (1998) J. Mol. Biol. 280, 485-500[CrossRef][Medline] [Order article via Infotrieve]
15. Medkova, M., and Cho, W. (1999) J. Biol. Chem. 274, 19852-19861[Abstract/Free Full Text]
16. Lomasney, J. W., Cheng, H. F., Roffler, S. R., and King, K. (1999) J. Biol. Chem. 274, 21995-22001[Abstract/Free Full Text]
17. Ananthanarayanan, B., Das, S., Rhee, S. G., Murray, D., and Cho, W. (2002) J. Biol. Chem. 277, 3568-13174[Abstract/Free Full Text]
18. Nalefski, E. A., McDonagh, T., Somers, W., Seehra, J., Falke, J. J., and Clark, J. D. (1998) J. Biol. Chem. 273, 1365-1372[Abstract/Free Full Text]
19. Kulkarni, S., Das, S., Funk, C. D., Murray, D., and Cho, W. (2002) J. Biol. Chem. 277, 13167-13174[Abstract/Free Full Text]
20. Corbalan-Garcia, S., Rodriguez-Alfaro, J. A., and Gomez-Fernandez, J. C. (1999) Biochem. J. 337, 513-521[CrossRef][Medline] [Order article via Infotrieve]
21. Perisic, O., Paterson, H. F., Mosedale, G., Lara-Gonzalez, S., and Williams, R. L. (1999) J. Biol. Chem. 274, 14979-14987[Abstract/Free Full Text]
22. Gijon, M. A., Spencer, D. M., Kaiser, A. L., and Leslie, C. C. (1999) J. Cell Biol. 145, 1219-1232[Abstract/Free Full Text]
23. Gerber, S. H., Rizo, J., and Sudhof, T. C. (2001) J. Biol. Chem. 276, 32288-32292[Abstract/Free Full Text]
24. Conesa-Zamora, P., Lopez-Andreo, M. J., Gomez-Fernandez, J. C., and Corbalan-Garcia, S. (2001) Biochemistry 40, 13898-13905[CrossRef][Medline] [Order article via Infotrieve]
25. Kates, M. (1986) Techniques of Lipidology , 2nd Ed. , pp. 113-116, Elsevier, Amsterdam
26. Bittova, L., Sumandea, M., and Cho, W. (1999) J. Biol. Chem. 274, 9665-9672[Abstract/Free Full Text]
27. Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K., and Pease, L. R. (1989) Gene 77, 51-59[CrossRef][Medline] [Order article via Infotrieve]
28. Medkova, M., and Cho, W. (1998) J. Biol. Chem. 273, 17544-17552[Abstract/Free Full Text]
29. Stahelin, R. V., and Cho, W. (2001) Biochemistry 40, 4672-4678[CrossRef][Medline] [Order article via Infotrieve]
30. Bittova, L., Stahelin, R. V., and Cho, W. (2001) J. Biol. Chem. 276, 4218-4226[Abstract/Free Full Text]
31. Cho, W., Bittova, L., and Stahelin, R. V. (2001) Anal. Biochem. 296, 153-161[CrossRef][Medline] [Order article via Infotrieve]
32. Schuck, P. (1997) Annu. Rev. Biophys. Biomol. Struct. 26, 541-566[CrossRef][Medline] [Order article via Infotrieve]
33. Myszka, D. G. (1997) Curr. Opin. Biotechnol. 8, 50-57[CrossRef][Medline] [Order article via Infotrieve]
34. Grynkiewicz, G., Poenie, M., and Tsien, R. Y. (1985) J. Biol. Chem. 260, 3440-3450[Abstract]
35. Haugland, R. P. (1996) Handbook of Fluorescent Probes and Research Chemicals , 6th Ed. , Molecular Probes, Inc., Eugene, OR
36. Stahelin, R. V., and Cho, W. (2001) Biochem. J. 359, 679-685[CrossRef][Medline] [Order article via Infotrieve]
37. Oancea, E., and Meyer, T. (1998) Cell 95, 307-318[Medline] [Order article via Infotrieve]
38. Sakai, N., Sasaki, K., Ikegaki, N., Shirai, Y., Ono, Y., and Saito, N. (1997) J. Cell Biol. 139, 1465-1476[Abstract/Free Full Text]
39. Oancea, E., Teruel, M. N., Quest, A. F., and Meyer, T. (1998) J. Cell Biol. 140, 485-498[Abstract/Free Full Text]
40. Ohmori, S., Shirai, Y., Sakai, N., Fujii, M., Konishi, H., Kikkawa, U., and Saito, N. (1998) Mol. Cell. Biol. 18, 5263-5271[Abstract/Free Full Text]
41. Almholt, K., Arkhammar, P. O., Thastrup, O., and Tullin, S. (1999) Biochem. J. 337, 211-218[CrossRef][Medline] [Order article via Infotrieve]
42. Glover, S., de Carvalho, M. S., Bayburt, T., Jonas, M., Chi, E., Leslie, C. C., and Gelb, M. H. (1995) J. Biol. Chem. 270, 15359-15367[Abstract/Free Full Text]
43. Evans, J. H., Spencer, D. M., Zweifach, A., and Leslie, C. C. (2001) J. Biol. Chem. 276, 30150-30160[Abstract/Free Full Text]
44. McMurray. (1973) in Form and Function of Phospholipids (Ansell, G. B. , Hawthorne, J. N. , and Dawson, R. M. C., eds) , pp. 205-251, Elsevier, Amsterdam
45. Zachowski, A. (1993) Biochem. J. 294, 1-14[Medline] [Order article via Infotrieve]
46. Gelb, M. H., Cho, W., and Wilton, D. C. (1999) Curr. Opin. Struct. Biol. 9, 428-432[CrossRef][Medline] [Order article via Infotrieve]
47. Han, S. K., Kim, K. P., Koduri, R., Bittova, L., Munoz, N. M., Leff, A. R., Wilton, D. C., Gelb, M. H., and Cho, W. (1999) J. Biol. Chem. 274, 11881-11888[Abstract/Free Full Text]
48. Sutton, R. B., and Sprang, S. R. (1998) Structure 6, 1395-1405[Medline] [Order article via Infotrieve]
49. Nalefski, E. A., and Falke, J. J. (1998) Biochemistry 37, 17642-17650[CrossRef][Medline] [Order article via Infotrieve]
50. Ball, A., Nielsen, R., Gelb, M. H., and Robinson, B. H. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 6637-6642[Abstract/Free Full Text]
51. Mochly-Rosen, D., and Gordon, A. S. (1998) FASEB J. 12, 35-42[Abstract/Free Full Text]
52. Nakatani, Y., Tanioka, T., Sunaga, S., Murakami, M., and Kudo, I. (2000) J. Biol. Chem. 275, 1161-1168[Abstract/Free Full Text]
53. Bretscher, M. S. (1972) Nat. New Biol. 236, 11-12[Medline] [Order article via Infotrieve]
54. Daum, G. (1985) Biochim. Biophys. Acta 822, 1-42[Medline] [Order article via Infotrieve]
55. Williams, S. D., Hsu, F. F., and Ford, D. A. (2000) J. Lipid Res. 41, 1585-1595[Abstract/Free Full Text]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.